StockData
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$9.85−0.28 (-2.76%)

Close on Nov 17, 2026Market cap $612.26MP/E –Yield –

Sagimet Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Sagimet Biosciences's revenue for the twelve months ending Dec 31, 2023 was $2.00M. For fiscal 2023 it was $2.00M.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$2.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$2.00M–

More Sagimet Biosciences figures

See a number that looks wrong?